Citation & Authors
J Intern Med. 2025;297(5):532-542.
ABSTRACT · RESEARCH SUMMARY
Research summary
The study matched 1,063 pairs of patients with diabetes after heart transplantation. SGLT2 inhibitor users had lower risks of dialysis (HR 0.566; 95% CI 0.385–0.833), graft rejection/failure, hospitalization, and death. Infection/sepsis, ischemic heart disease, and worsening heart failure did not differ significantly. These multicenter observational findings do not establish causal benefit.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
